Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 311.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,776 shares of the company’s stock after acquiring an additional 9,672 shares during the period. JPMorgan Chase & Co.’s holdings in Eliem Therapeutics were worth $65,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC grew its position in shares of Eliem Therapeutics by 10.8% during the third quarter. Janus Henderson Group PLC now owns 3,606,495 shares of the company’s stock worth $18,303,000 after buying an additional 352,507 shares in the last quarter. Ally Bridge Group NY LLC raised its stake in shares of Eliem Therapeutics by 145.9% during the 3rd quarter. Ally Bridge Group NY LLC now owns 1,229,292 shares of the company’s stock worth $6,257,000 after buying an additional 729,292 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Eliem Therapeutics during the 3rd quarter worth $3,008,000. State Street Corp raised its stake in shares of Eliem Therapeutics by 433.9% during the 3rd quarter. State Street Corp now owns 315,036 shares of the company’s stock worth $1,604,000 after buying an additional 256,029 shares during the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in shares of Eliem Therapeutics during the 3rd quarter worth $1,419,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

Eliem Therapeutics Trading Down 1.6 %

Eliem Therapeutics stock opened at $1.90 on Tuesday. The stock has a market cap of $56.53 million, a PE ratio of -3.58 and a beta of -0.39. The stock has a 50-day moving average price of $2.31 and a 200 day moving average price of $4.63. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.